目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T6421 | HDAC | ||
BRD73954 是一种有效且特异性的 HDAC 抑制剂,对 HDAC6 和 HDAC8 的 IC50 分别为 36 nM 和 120 nM。 | |||
T4370 | HDAC | ||
Resminostat hydrochloride (RAS2410 hydrochloride) 是HDAC1,HHDAC3和HDAC6抑制剂,IC50值分别为 42.5、50.1和71.8 nM,对 HDAC8 的活性较低,IC50值为 877 nM。 | |||
T77334 | Apoptosis HDAC | ||
HDAC-IN-57 是一种具有口服活性的组蛋白脱乙酰酶 (HDAC) 泛抑制剂,对 HDAC1, HDAC2, HDAC6, HDAC8 具有抑制作用, IC50 值分别为 2.07 nM, 4.71 nM, 2.4 nM 和 107 nM。HDAC-IN-57 对 LSD1具有抑制作用, IC50 值为 1.34 μΜ。HDAC-IN-57 具有抗肿瘤活性,可诱导凋亡 (apoptosis)。 | |||
T14947 | HDAC | ||
CHDI-390576 is a CNS penetrant class IIa HDAC inhibitor (IC50s: 54 nM, 60 nM, 31 nM, 50 nM for class IIa HDAC4, HDAC5, HDAC7, HDAC9). It shows >500-fold selectivity over class I HDACs (1, 2, 3) and ~150-fold selectivity over HDAC8 and the class IIb HDAC6 isoform. | |||
T10883 | HDAC | ||
CRA-026440(PCI-34051) 是一种高效的 HDAC 抑制剂,对 HDAC1,HDAC2,HDAC3,HDAC6,HDAC8 和 HDAC10 具有抑制作用, Ki 值分别为 4,14,11,15,7 和 20 nM。CRA-026440 具有抗肿瘤和抗血管生成活性,可用于研究结肠癌。 | |||
T6161 | Apoptosis HDAC Autophagy | ||
Tubastatin A Hydrochloride (TSA HCl) 是一种选择性的 HDAC6抑制剂,IC50值为 15 nM,对其选择性是 HDAC8 外的其他亚型的 1000 多倍。 | |||
T0431 | HDAC | ||
Abexinostat (PCI24781) 是一种新型的泛HDAC 抑制剂,对HDAC1的Ki 值为7 nM。 | |||
T1966 | Apoptosis HDAC Autophagy | ||
Tubastatin A (Tubastatin A BASE) 是一种选择性 HDAC6抑制剂,IC50值为 15 nM。 | |||
T10883L | HDAC | ||
CRA-026440 hydrochloride 是有效的、广谱的 HDAC 抑制剂。CRA-026440 hydrochloride 作用于 HDAC1,HDAC2,HDAC3,HDAC6,HDAC8 和 HDAC10, Ki 值分别为 4 nM,14 nM,11 nM,15 nM,7 nM 和 20 nM。CRA-026440 hydrochloride 具有抗血管生成和抗肿瘤活性。 | |||
T8480 | Dehydrogenase Sirtuin HDAC p53 Autophagy | ||
Tenovin-6 Hydrochloride 是 Tenovin-1 的类似物,能抑制二氢乳清酸脱氢酶。它是一种 p53转录活性的激活剂,抑制纯化人 SIRT1、SIRT2 和 SIRT3 蛋白脱乙酰酶活性,IC50分别为 21 μM、10 μM 和 67 μM。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-02317 | HDAC8 Protein, Mouse, Recombinant (His) | Mouse | Baculovirus-Insect Cells | ||
Histone deacetylase 8, also known as HDAC8 and HDACL1, is a nucleus and cytoplasm protein that belongs to the histone deacetylase family and HD type 1 subfamily. Histone deacetylases (HDACs) are a growing family of enzymes implicated in transcriptional regulation by affecting the acetylation state of core histones in the nucleus of cells. HDAC8 / HDACL1 is weakly expressed in most tissues. It is expressed at a higher level in the heart, brain, kidney, and pancreas and also in the liver, lung, placenta, prostate, and kidney. HDAC8 / HDACL1 is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones ( H2A, H2B, H3, and H4 ). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression, and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. HDAC8 / HDACL1 may play a role in smooth muscle cell contractility. HDAC8 / HDACL1 may be a potential drug target for neuroblastoma differentiation therapy using selective inhibitors, avoiding unspecific side effects.
|
|||||
TMPY-01333 | HDAC8 Protein, Human, Recombinant (GST) | Human | Baculovirus-Insect Cells | ||
Histone deacetylase 8, also known as HDAC8 and HDACL1, is a nucleus and cytoplasm protein that belongs to the histone deacetylase family and HD type 1 subfamily. Histone deacetylases (HDACs) are a growing family of enzymes implicated in transcriptional regulation by affecting the acetylation state of core histones in the nucleus of cells. HDAC8 / HDACL1 is weakly expressed in most tissues. It is expressed at a higher level in the heart, brain, kidney, and pancreas and also in the liver, lung, placenta, prostate, and kidney. HDAC8 / HDACL1 is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones ( H2A, H2B, H3, and H4 ). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression, and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. HDAC8 / HDACL1 may play a role in smooth muscle cell contractility. HDAC8 / HDACL1 may be a potential drug target for neuroblastoma differentiation therapy using selective inhibitors, avoiding unspecific side effects.
|